KNSA FY 2025 Earnings — Kiniksa Pharmaceuticals, Ltd. Revenue & Financial Results | Market Cap Arena

KNSAKiniksa Pharmaceuticals, Ltd.

$3B

FY 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$678M+60.1% YoY

Gross Profit

$370M54.6% margin

Operating Income

$77M11.4% margin

Net Income

$59M8.7% margin

EPS (Diluted)

$0.75

Cash Flow

Operating Cash Flow

$26M

Free Cash Flow

$25M

Stock-Based Comp.

$31M

Balance Sheet

Total Assets

$764M

Total Liabilities

$196M

Stockholders' Equity

$568M

Cash & Equivalents

$166M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$678M	$423M	+60.1%
Gross Profit	$370M	$362M	+2.2%
Operating Income	$77M	-$46M	+269.3%
Net Income	$59M	-$43M	+236.6%